See more : Clime Capital Limited (CAM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Develop Global Limited (DVP.AX) Income Statement Analysis – Financial Results
- Spectra7 Microsystems Inc. (SEV.V) Income Statement Analysis – Financial Results
- Rockwool A/S (ROCK-B.CO) Income Statement Analysis – Financial Results
- Paladin Energy Ltd (PDN.AX) Income Statement Analysis – Financial Results
- Yancoal Australia Ltd (3668.HK) Income Statement Analysis – Financial Results
Aeglea BioTherapeutics, Inc. (AGLE)
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Other Expenses | -7.00K | -122.00K | -5.00K | -63.00K | -57.00K | -42.00K | -36.00K | -2.00K | 0.00 |
| Operating Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Cost & Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 837.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -84.78M | -65.65M | -80.49M | -80.33M | -44.06M | -27.68M | -21.77M | -11.23M | -7.44M |
| EBITDA Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,133.10% | -531.72% | -470.48% | -184.49% | 0.00% |
| Operating Income | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | 830.00K | -11.00K | 588.00K | 2.08M | -57.00K | -42.00K | -36.00K | 20.00K | -1.44M |
| Income Before Tax | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -136.00K | 141.00K | -593.00K | -2.56M | -57.00K | -731.00K | -244.00K | -22.00K | 1.44M |
| Net Income | -83.82M | -65.80M | -80.30M | -75.69M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| EPS Diluted | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| Weighted Avg Shares Out | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
| Weighted Avg Shares Out (Dil) | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022
AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in two investor conferences as...
3 Biotech Stocks That Sank: Are Any a Bad-News Buy?
At least one of the three could be in store for better news in the future.
Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur...
Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency
AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference...
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June...
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease
AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from...
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jonathan D. Alspaugh as Chief...
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria
AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the dosing of the first patient in...
Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea's pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily metabolic enzyme-related indications including arginase 1...
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial results, and provided...
Source: https://incomestatements.info
Category: Stock Reports